Why The Bear Attack On Teva Pharmaceutical Must End

|
About: Teva Pharmaceutical Industries Limited (TEVA)
by: Chris Lau
This article is exclusive for subscribers.
Chris Lau
Contrarian, event-driven, tech, oil & gas
Summary

Renewed bearishness on Teva over the opioid subpoena may prove short-lived.

Third-quarter results a positive inflection point.

Business recovery underway.

Teva Pharmaceutical (NYSE:TEVA) barely settled back to the double-digit $10 range when WSJ sources reported that Federal prosecutors will include it in an investigation. If true, the rally in TEVA stock will take